How to buy Zogenix stock - 15 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Zogenix stock

Own Zogenix stock in just a few minutes.

Zogenix, Inc is a biotechnology business based in the US. Zogenix shares (ZGNX) are listed on the NASDAQ and all prices are listed in US Dollars. Zogenix employs 218 staff and has a trailing 12-month revenue of around USD$13.6 million.

How to buy shares in Zogenix

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Zogenix. Find the stock by name or ticker symbol: ZGNX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Zogenix reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Zogenix, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Zogenix. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Zogenix share price

Use our graph to track the performance of ZGNX stocks over time.

Zogenix shares at a glance

Information last updated 2021-04-09.
52-week rangeUSD$17.2033 - USD$32.42
50-day moving average USD$20.5509
200-day moving average USD$20.3837
Wall St. target priceUSD$48.7
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.32

Buy Zogenix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Zogenix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zogenix financials

Revenue TTM USD$13.6 million
Gross profit TTM USD$-124,901,000
Return on assets TTM -26.8%
Return on equity TTM -68.12%
Profit margin 0%
Book value $6.632
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Zogenix shares

There are currently 8.8 million Zogenix shares held short by investors – that's known as Zogenix's "short interest". This figure is 1.3% down from 8.9 million last month.

There are a few different ways that this level of interest in shorting Zogenix shares can be evaluated.

Zogenix's "short interest ratio" (SIR)

Zogenix's "short interest ratio" (SIR) is the quantity of Zogenix shares currently shorted divided by the average quantity of Zogenix shares traded daily (recently around 709409.59677419). Zogenix's SIR currently stands at 12.4. In other words for every 100,000 Zogenix shares traded daily on the market, roughly 12400 shares are currently held short.

However Zogenix's short interest can also be evaluated against the total number of Zogenix shares, or, against the total number of tradable Zogenix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zogenix's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Zogenix shares in existence, roughly 160 shares are currently held short) or 0.1586% of the tradable shares (for every 100,000 tradable Zogenix shares, roughly 159 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Zogenix.

Find out more about how you can short Zogenix stock.

Zogenix share dividends

We're not expecting Zogenix to pay a dividend over the next 12 months.

Have Zogenix's shares ever split?

Zogenix's shares were split on a 1:8 basis on 30 June 2015. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Zogenix shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Zogenix shares which in turn could have impacted Zogenix's share price.

Zogenix share price volatility

Over the last 12 months, Zogenix's shares have ranged in value from as little as $17.2033 up to $32.42. A popular way to gauge a stock's volatility is its "beta".

ZGNX.US volatility(beta: 1.46)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zogenix's is 1.4606. This would suggest that Zogenix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Zogenix overview

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site